Suk Young
Suk Young Bae, Seoul KR
Patent application number | Description | Published |
---|---|---|
20130140539 | HOST MATERIAL AND ORGANIC LIGHT EMITTING DISPLAY DEVICE USING THE SAME - A host material is disclosed. The host material, as a compound which is represented by the following formula 1, has a chemical structure in which nitrogen and silicon atoms are chemically and directly bonded to each other. | 06-06-2013 |
20150162537 | ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DIODE USING THE SAME - Discussed is an organic electroluminescent device including a first charge carrying layer being disposed adjacent to a first electrode; and a second charge carrying layer disposed adjacent to a second electrode, wherein the first charge carrying layer includes an emitting part, a hole injection part and a hole transporting part between the hole injection part and the emitting part, wherein at least one of the hole injection part, the hole transporting part and the emitting part includes a host material having an organic compound of Formula: | 06-11-2015 |
Suk Young Cho, Sejong KR
Patent application number | Description | Published |
---|---|---|
20160108041 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS - The invention provides novel substituted heterocyclic compounds represented by Formula I and Formula II, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans. | 04-21-2016 |
Suk Young Cho, Seongnam KR
Patent application number | Description | Published |
---|---|---|
20120238587 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF - The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders. | 09-20-2012 |
20150158874 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF - The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders. | 06-11-2015 |
Suk Young Cho, Gyeonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20090312383 | Fused Heterocyclic Compounds - There is provided a CRF receptor antagonist comprising a compound of the formula (I): | 12-17-2009 |
20100056515 | BENZIMIDAZOLE COMPOUNDS - There is provided a compound of the formula (I): | 03-04-2010 |
Suk Young Cho, Seongnam-Si KR
Patent application number | Description | Published |
---|---|---|
20140113915 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF - The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders. | 04-24-2014 |
Suk Young Choi, Daejeon KR
Patent application number | Description | Published |
---|---|---|
20080260654 | Sustained Release Composition of Protein Drug - Disclosed is a sustained release composition of a protein drug. The composition comprises a carrier substrate and a protein drug incorporated in the carrier substrate. The carrier substrate is consisting essentially of a hyaluronic acid or its salts, an amino acid, and a polyalkyl oxide. | 10-23-2008 |
20110201554 | HFSH AQUEOUS FORMULATION - Provided is an aqueous formulation of a human follicle stimulating hormone (hFSH) which is stabilized to maintain the activity of hFSH for a prolonged period of time. The formulation of the present invention is an aqueous formulation comprising a therapeutically effective amount of hFSH stabilized in a phosphate buffer containing glycine, methionine and a non-ionic surfactant, preferably polysorbate 20, which is capable of maintaining the activity of hFSH for an extended period of time. | 08-18-2011 |
20140199303 | Stable Liquid Formulation of Etanercept - The present invention relates to a stable liquid formulation of etanercept (recombinant p75 sTNFR:Fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage. Therefore, the reconstitution procedure is not required before administration, and the sterile formulation can be administered to patients to ensure patient safety. Thus, it can be applied to the fields in need of etanercept treatment. | 07-17-2014 |
Suk Young Lee, Seongnam-Si KR
Patent application number | Description | Published |
---|---|---|
20120278462 | UNIFIED COMMUNICATION SYSTEM AND UNIFIED COMMUNICATION METHOD USING MULTI-LOGIN, TERMINAL FOR CONTROLLING OPERATION OF UNIFIED COMMUNICATION TOOL, AND COMMUNICATION METHOD IN TERMINAL - Provided are a unified communication system and a unified communication method using multi-login, a terminal for controlling an operation of a unified communication tool, and a communication method in a terminal. The unified communication system may include a communication tool provider to provide a communication tool for at least one communication server associated with a user; a login manager to manage login information of the user when the user is logged in to two or more terminals simultaneously through respective communication tools on the two or more terminals, respectively, the login manager storing the login information of the user in a storage unit; a terminal determining unit to determine, among the two or more terminals, at least one terminal to which data associated with the user is to be transmitted based on the login information; and a communication unit to transmit the data to the at least one determined terminal. | 11-01-2012 |
20120296989 | FILE TRANSMISSION MANAGEMENT SYSTEM AND FILE TRANSMISSION MANAGEMENT METHOD FOR SUPPORTING FILE TRANSMISSION IN MOBILE MESSAGING SERVICE - Exemplary embodiments of the present invention disclose a file transmission management system and a file transmission management method for supporting a file transmission in a mobile messaging service. The file transmission management system may include a file transmission manager to receive a file from an Internet storage space associated with a user when the user requests a transmission of the file stored in the Internet storage space. | 11-22-2012 |